Y Intercept Hong Kong Ltd Cuts Stock Holdings in Acadia Healthcare Company, Inc. (NASDAQ:ACHC)

Y Intercept Hong Kong Ltd reduced its position in Acadia Healthcare Company, Inc. (NASDAQ:ACHC) by 20.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 29,045 shares of the company’s stock after selling 7,560 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Acadia Healthcare were worth $1,152,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ACHC. State Street Corp raised its stake in shares of Acadia Healthcare by 3.5% in the third quarter. State Street Corp now owns 2,819,911 shares of the company’s stock worth $178,811,000 after purchasing an additional 95,613 shares during the last quarter. JPMorgan Chase & Co. raised its position in Acadia Healthcare by 17.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,126,607 shares of the company’s stock worth $198,258,000 after buying an additional 454,044 shares during the last quarter. SG Americas Securities LLC lifted its stake in Acadia Healthcare by 713.3% during the 4th quarter. SG Americas Securities LLC now owns 110,866 shares of the company’s stock valued at $4,396,000 after acquiring an additional 97,235 shares during the period. Beach Point Capital Management LP purchased a new stake in shares of Acadia Healthcare during the 4th quarter valued at about $14,097,000. Finally, LMR Partners LLP bought a new stake in shares of Acadia Healthcare in the third quarter worth approximately $1,616,000.

Acadia Healthcare Trading Down 3.2 %

Shares of NASDAQ:ACHC opened at $41.00 on Thursday. The stock has a 50 day moving average of $42.22 and a 200 day moving average of $52.30. The company has a market cap of $3.81 billion, a PE ratio of 13.44, a price-to-earnings-growth ratio of 1.46 and a beta of 1.30. Acadia Healthcare Company, Inc. has a 12-month low of $36.50 and a 12-month high of $87.77. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.60.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ACHC. Deutsche Bank Aktiengesellschaft upgraded shares of Acadia Healthcare from a “hold” rating to a “buy” rating and increased their price objective for the company from $45.00 to $75.00 in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and issued a $64.00 price target on shares of Acadia Healthcare in a research note on Friday, January 10th. KeyCorp upgraded Acadia Healthcare from a “sector weight” rating to an “overweight” rating and set a $70.00 price objective for the company in a research report on Tuesday, January 7th. StockNews.com cut Acadia Healthcare from a “hold” rating to a “sell” rating in a research report on Monday, January 6th. Finally, Barclays reduced their price target on shares of Acadia Healthcare from $76.00 to $43.00 and set an “overweight” rating for the company in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $70.22.

About Acadia Healthcare

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.